At the 2026 ASCO Genitourinary Cancers Symposium, Dr. Andrea Necchi shared the final results of the SunRISe-2 phase 3 trial, ...
In an interview, C. Ola Landgren, MD, PhD, delved into the details of the FDA's draft guidance on using MRD as a basis for ...
Antonio Ocejo, MD, discussed a multi-institutional analysis focusing on the clinical outcomes and tolerability of ipilimumab ...
During a live event, Shaji Kumar, MD, discussed when talquetamab can be sequenced in multiple myeloma as an alternative to targeting BCMA in consecutive lines. Patients with relapsed/refractory ...
“Incorporating ctDNA into the decision-making process helps refine who can safely keep their bladder,” Ghatalia, associate professor, Department of Hematology/Oncology, at Fox Chase Cancer Center in ...
Results from the phase 2 Daro-PET study (NCT05900973) showed that prostate-specific membrane antigen (PSMA) expression was boosted with short-course darolutamide (Nubeqa) in patients with high-risk ...
Divergence in the post-progression interval suggests disparities may concentrate in subsequent-line therapy, surveillance, supportive care, or access to timely interventions outside trial ...
The ongoing Daro-PET study set out to evaluate the ability of the oral androgen receptor inhibitor darolutamide (Nubeqa) to ...
The FDA has granted accelerated approval to zongertinib (Hernexeos) for the treatment of adults with unresectable or ...
During a live event, Daniel Olson, MD, discussed data and experience using tumor-infiltrating lymphocytes in melanoma.
Final overall survival data for PEACE-3 (NCT02194842) evaluating the combination of enzalutamide (Xtandi) and radium-223 ...
There is a lot that we learned from BOSTON, and there’s a lot that we’re still learning. There was a time where bortezomib was intravenous twice weekly. Now…it’s once weekly subcutaneous, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results